Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
16.17
-1.89 (-10.47%)
Nov 20, 2024, 4:00 PM EST - Market closed
ARCT Employees
Arcturus Therapeutics Holdings had 180 employees as of December 31, 2023. The number of employees increased by 10 or 5.88% compared to the previous year.
Employees
180
Change (1Y)
10
Growth (1Y)
5.88%
Revenue / Employee
$891,106
Profits / Employee
-$348,017
Market Cap
438.00M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| GRAIL | 1,360 |
| Treace Medical Concepts | 516 |
| MeiraGTx Holdings | 425 |
| Esperion Therapeutics | 240 |
| Acelyrin | 135 |
| Y-mAbs Therapeutics | 100 |
| Theravance Biopharma | 99 |
| Olema Pharmaceuticals | 74 |
ARCT News
- 2 days ago - Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Business Wire
- 6 days ago - Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data - Seeking Alpha
- 7 days ago - Meiji Seika Pharma Announces Investment in ARCALIS, Inc. - Business Wire
- 9 days ago - Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Business Wire
- 13 days ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - Business Wire
- 20 days ago - Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 - Business Wire
- 7 weeks ago - Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination - Business Wire